IGC Pharma Reports 50% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial

Core Insights - IGC Pharma, Inc. has achieved a significant enrollment milestone of 50% in its Phase 2 CALMA clinical trial for IGC-AD1, aimed at treating agitation in Alzheimer's disease [1] Company Summary - IGC Pharma, Inc. is a clinical-stage pharmaceutical company focused on developing therapies specifically for Alzheimer's disease [1] - The company's proprietary formulation, IGC-AD1, combines low concentrations of delta-9 tetrahydrocannabinol (THC) with another active pharmaceutical ingredient [1] Industry Context - The advancement of clinical trials for Alzheimer's disease therapies is critical, given the increasing prevalence of the condition and the need for effective treatments [1]